INBX:NASDAQInhibrx Biosciences, Inc. analysis
Data as of Sep 30, 2026 - not real-time
- Latest price
- $104.83
- Risk: high
- 9/10High risk
Summary
At $104.83, Inhibrx Biosciences, Inc. shows a bullish moving-average alignment, with shorter averages sitting above longer ones. Over a rolling month the price has gained 13.9%. With RSI at 48.0 the momentum picture is neutral, alongside a bearish MACD signal. Price has been bracketed by support at $94.00 and resistance at $129.88.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Analyst price targets sit 154.4% above the current price.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 70.0%, a beta of 2.58 and a maximum drawdown of 44.1%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
The horizons line up on hold — conviction 1 out of 10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Analyst price targets sit 154.4% above the current price.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 70.0%, a beta of 2.58 and a maximum drawdown of 44.1%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
The horizons line up on hold — conviction 1 out of 10.
Top market events
- SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. Nasdaq: INBX "Inhibrx" or the "Company" today...
- /PRNewswire/ -- Inhibrx Biosciences, Inc.
- Inhibrx stock is holding well above its 52-week low, with recent filings highlighting institutional
Market outlook
Short term
< 1 yearNeutral
Model confidence2/102 out of 10
Key factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 90.79
- MACD momentum is negative
Medium term
1–3 yearsNeutral
Model confidence1/101 out of 10
Key factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 90.79
- Analyst targets imply +154.4% versus the current price
Long term
> 3 yearsNeutral
Model confidence1/101 out of 10
Key factors
- Analyst targets imply +154.4% versus the current price
- Negative return on equity of -1773.6%
- Negative free cash flow
Key metrics
Financial health
P/E Ratio-12.0
ROE-1773.60%
ROA-43.61%
P/B Ratio-29.1
Op. Cash Flow$-131889000
Free Cash Flow$-85104872
Industry P/E30.5
Technical analysis
TrendBullish
RSI48.0
Support$94.00
Resistance$129.88
MA 20$110.12
MA 50$101.25
MA 200$90.79
MACDBearish
VolumeDecreasing
Fear & Greed Index93.05
Valuation
Target Price$266.67
Upside/Downside154.38%
GradeFair
TypeBlend
Risk assessment
Beta2.58
Volatility70.03%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.